IL-12 engineered immune cells for relapsed solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new treatment that uses your own immune cells, modified to produce IL-12, to fight solid tumors that have come back or not responded to other therapies. It aims to see if this approach is safe and can shrink or control cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor cancer that has come back or hasn't responded to standard treatments.
- You are 18 years or older and able to walk (or use a wheelchair independently).
- You have adequate organ function (kidneys, liver, heart, lungs) as shown by blood tests and scans.
- If you are willing to have tumor biopsies (for Part B), you must be able to have them safely.
- You must agree to use effective birth control for up to 12 months after treatment (if applicable).
- You must be willing to be followed long-term for any delayed side effects of gene therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies the safety of an investigational drug called IL-12-L19L19 and looks for early signs it may help control advanced (metastatic) solid tumors. It is designed for people whose cancer has continued to grow even after treatment with immune “checkpoint” therapies.
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
This trial tests a treatment that takes immune cells from your tumor, multiplies them in a lab, and gives them back to you to fight the cancer. It is for people with advanced solid tumors who have tried other treatments or cannot have them.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests an immunotherapy made from your own tumor-fighting immune cells (TIL). It may help people with advanced solid cancers that cannot be cured with surgery or radiation.
This early-stage trial tests a new type of immune cell therapy (NK cells boosted with a protein called IL-15) to treat solid cancers that have spread or come back after standard treatment. The goal is to see if this approach can help shrink tumors and improve survival.
Hear when a new Relapsed Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.